Citigroup
BCYC

Citigroup’s Bicycle Therapeutics BCYC Stock Holding History

Citigroup’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.98K Sell
1,175
-120
-9% -$550 ﹤0.01% 5311
2026
Q1 		$6.01K Buy
1,295
+4
+0.3% +$23 ﹤0.01% 5211
2025
Q4 		$9.14K Sell
1,291
-1,310
-50% -$9.66K ﹤0.01% 5090
2025
Q3 		$20.1K Buy
2,601
+1,688
+185% +$12.7K ﹤0.01% 4812
2025
Q2 		$6.34K Buy
913
+224
+33% +$1.78K ﹤0.01% 5251
2025
Q1 		$5.85K Buy
689
+59
+9% +$695 ﹤0.01% 5260
2024
Q4 		$8.82K Sell
630
-38
-6% -$814 ﹤0.01% 5402
2024
Q3 		$15.1K Sell
668
-94
-12% -$2.17K ﹤0.01% 5230
2024
Q2 		$15.4K Buy
762
+634
+495% +$14.3K ﹤0.01% 5059
2024
Q1 		$3.19K Sell
128
-15,500
-99% -$329K ﹤0.01% 5359
2023
Q4 		$283K Buy
15,628
+15,096
+2,838% +$250K ﹤0.01% 3754
2023
Q3 		$10.7K Sell
532
-71
-12% -$1.62K ﹤0.01% 4526
2023
Q2 		$15.4K Buy
603
+148
+33% +$3.44K ﹤0.01% 5007
2023
Q1 		$9.68K Sell
455
-56
-11% -$1.4K ﹤0.01% 4745
2022
Q4 		$15.1K Sell
511
-23
-4% -$617 ﹤0.01% 4702
2022
Q3 		$12K Sell
534
-55
-9% -$1.31K ﹤0.01% 4920
2022
Q2 		$10K Sell
589
-159
-21% -$3.35K ﹤0.01% 5354
2022
Q1 		$33K Sell
748
-54
-7% -$2.52K ﹤0.01% 4904
2021
Q4 		$49K Buy
802
+649
+424% +$35.8K ﹤0.01% 5069
2021
Q3 		$6K Sell
153
-913
-86% -$31.9K ﹤0.01% 5565
2021
Q2 		$32K Buy
1,066
+553
+108% +$16.7K ﹤0.01% 5039
2021
Q1 		$15K Buy
+513
New +$13.2K ﹤0.01% 5394

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citigroup's BCYC Position: Q2 2026 in Review

Citigroup reduced its Bicycle Therapeutics (BCYC) stake by 9.3% in Q2 2026, selling an estimated $550 and leaving 1,175 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #5311.

Citigroup first reported a position in BCYC in Q1 2021 and has held it in 22 quarters since. The position peaked at $283K in Q4 2023. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Citigroup held 1,175 shares of Bicycle Therapeutics worth $4.98K as of Q2 2026.
  • Citigroup sold 120 Bicycle Therapeutics shares in Q2 2026, an estimated $550.
  • Bicycle Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5311 holding.
  • Citigroup first reported a position in Bicycle Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Citigroup's Bicycle Therapeutics position peaked at $283K in Q4 2023.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.